Barcelona-based Almirall SA is deepening its reliance on generative artificial intelligence (GenAI) for drug discovery and development. The company, which specializes in dermatological indications, entered a three-year collaboration with Microsoft to employ the big tech’s GenAI and advanced analytics capabilities to analyze datasets and strengthen its own technology platform.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?